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SUMMARY
What is known and Objective: To determine to what extent
patient interviews contribute to the identification of drug-
related problems (DRPs) in home medication reviews, in
terms of number, type and clinical relevance.
Methods: We performed a cross-sectional study within the
intervention arm of a randomized controlled trial. Patients
were recruited from 10 Dutch community pharmacies. Patients
were eligible if they were home-dwelling, aged 65 years and
over and used five or more different drugs, including at least
one cardiovascular or antidiabetic drug. The community phar-
macist interviewed the patient at home about the medicines
and identified potential DRPs in combination with medication
and clinical records. This medication review was assessed and
modified by an independent pharmacist reviewers’ panel.
Outcomes were the number and type of DRPs and recommen-
dations and percentage of clinical relevant DRPs. Clinical rel-
evance of DRPs was assessed by DRPs assigned a high
priority, DRPs followed by recommendations for drug change
and DRPs followed by implemented recommendations for
drug change.
Results: A total of 1565 potential DRPs and recommendations
(10 per patient).were identified for 155 patients (median age,
76 years; 54% women). Fifty-eight per cent of all recommenda-
tions involved a drug change; 27% of all DRPs were identified
during patient interviews and 74% from medication and clinical
records. Compared to DRPs identified from patient medication
and clinical records, DRPs identified during patient interviews
were more frequently assigned a high priority (OR = 1Æ8 [1Æ4–
2Æ2]), were more frequently associated with recommendations
for drug change (OR = 2Æ4 [1Æ9–3Æ1]) and were implemented rec-
ommendations for drug change (OR = 2Æ8 [2Æ1–3Æ7]).
What is new and Conclusion: This study shows that more than
a quarter of all DRPs were identified during patient inter-
views. DRPs identified during patient interviews were more
frequently assigned a higher clinical relevance.
WHAT IS KNOWN AND OBJECTIVE
Studies have identified potential drug-related problems (DRPs)
during different types of medication review.1–8 Medication
reviews can be solely based on patient medication and clinical
records,1,2 but can also be combined with patient interviews.3–8
This more extensive review is known as a clinical medication
review.9
Patient interviews have been performed in several settings
such as hospitals,3 pharmacies,8 GPs’ offices4,7 or at the
patient’s home.5,6 In Australia, a patient interview at home by
an accredited pharmacist is the predominant method of clinical
medication review.5,10–12 In Europe, the patient is often invited
to the community pharmacy for an interview, as with the Med-
icine Use Review (MUR) in England.13 Different European
studies in primary care included patient interviews at
home,6,14–16 but these were not always conducted by a clini-
cally well-trained pharmacist and in close cooperation with a
GP, like in Australia.14–16
Although DRPs identified during patient interviews have
been shown to be clinically relevant, it is unclear to what extent
additional DRPs are identified when complete clinical and med-
ication records are available. Moreover, limited knowledge is
available on the clinical relevance of DRPs identified through
patient interviews compared to DRPs identified from clinical
and medication records.3
This study examines the contribution of a patient inter-
view to the identification of DRPs in home medication
review with the availability of complete dispensing and clin-
ical records. Moreover, we aimed to compare the clinical rel-
evance of DRPs identified during patient interviews to DRPs




This was a cross-sectional study within the intervention arm of
a randomized controlled trial (RCT) in a primary care setting.
This RCT aimed to assess whether home medication reviews
could reduce the number of DRPs and increase the proportion
of patients with adequate control of blood pressure, cholesterol
and HbA1C values. Patients were enrolled between February
2008 and August 2010.
Patients
Patients were recruited from 10 Dutch community pharma-
cies. Patients were eligible if they were home-dwelling, aged
65 years and over and used at least five oral prescription
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drugs, including at least one cardiovascular or one
antidiabetic drug. Consenting patients were visited and inter-
viewed face-to-face by a pharmacist at home. Patients were
excluded if the majority of drugs were prescribed by special-
ists.
Formal ethical approval was obtained from the medical ethi-
cal review board of the Utrecht University Medical Centre.
Patients gave written informed consent. To protect the patient’s
privacy, all medical data were anonymized by the community
pharmacist using a randomly assigned unique number for each
patient.
Intervention
For all patients, complete patient medication records from the
community pharmacy including drug dispensing records,
information on comorbidity, drug intolerances and other rele-
vant patient notes were available. Because the majority of
patients in the Netherlands are registered at only one commu-
nity pharmacy, independently of prescriber, patient medication
records are virtually complete with regard to prescription
drugs.17 The community pharmacists collected data from the
clinical records of the patient with the help from the GP prac-
tice, including medical history and laboratory data. As part of
the study protocol, patients were offered additional laboratory
measurements of HbA1C, cholesterol, sodium, potassium and
creatinine and blood pressure measurement. The patient’s
community pharmacist interviewed the patient at home aiming
to identify possible DRPs.
During the home visit, the community pharmacist evaluated
all medications that patients kept at home, including discontin-
ued prescription drugs, over-the-counter drugs and complemen-
tary and alternative medicines (patients indicated whether each
medication was currently taken). Community pharmacists had
limited experience with medication review. Therefore, they
received a 2-day training course in medication review as a part
of this study. Within this course, pharmacists were taught how
to perform a structured medication review and how to commu-
nicate with patients about adherence and understanding of the
drug therapy regimen and about patient’s experiences and con-
cerns regarding drug therapy (in particular, possible adverse
effects). GPs did not receive additional training in medication
review.
A pharmaceutical care plan was proposed by the community
pharmacist using both the patient medication and clinical
records (including additional laboratory data and blood pres-
sure collected as part of the study protocol) and the data from
the patient interview. These pharmaceutical care plans were
evaluated, if necessary adjusted, and completed by two inde-
pendent pharmacists from a pool of three pharmacist reviewers
(A.F; J.K.D; and H.K.). Pharmacist reviewers had several years
of experience with medication review, as well as in-depth
knowledge of national clinical guidelines.
Reviewers used both implicit and explicit criteria to iden-
tify potential DRPs. Explicit criteria consisted of a list of
clinical rules based on Dutch treatment and prescription
guidelines. Examples of clinical rules were ‘Lack of appro-
priate treatment for secondary prevention for CHD (antiplat-
elet, lipid-lowering, b-blocker, ACE-inhibitor)’, ‘Lack of
appropriate treatment for patients with diabetes and LDL
>2Æ5 mmol (lipid lowering)’ or ‘No available monitoring data
for blood pressure, lipids, glucose, BMI or data >1 year old
in patients for whom these measurements are indicated in
treatment guidelines’.18
Implicit criteria for identifying DRPs were based on a struc-
tural assessment as proposed by Cipolle et al. in the rational
order of indication, effectiveness, safety and compliance.19,20
The two reviewers reached consensus in a case conference. If no
consensus was met, the third reviewer was consulted until con-
sensus was reached. For example, when the two reviewers
could not agree (e.g. on the necessity of gastric protection with
a proton pump inhibitor in a geriatric patient using aspirin or
on the need to change the dosing time for simvastatin from the
afternoon to the evening).
Drug-related problems were prioritized by the pharmacist
reviewers as high, medium or low from the patient’s perspec-
tive, with the highest priority on those that cause the most con-
cern20 and need action. For example, high priority was assigned
to recommendations that could directly relief patient complaints
or to recommendations following on measurement of a deviat-
ing laboratory value or blood pressure.
The pharmaceutical care plans were sent to the community
pharmacist to be discussed in a case conference with the
patient’s GP within 4 weeks. DRPs with high priority were to
be discussed first with the GP, followed by DRPs with medium
priority, whereas DRPs with low priority were considerations
with low urgency.
Data classification
Drugs were classified using the Anatomical Therapeutic Chemi-
cal (ATC) classification. Potential DRPs were classified using the
D.O.C.U.M.E.N.T. classification system1,21,22 using the recently
updated version.23,24
All coding and classification were independently undertaken by
one investigator (H.K.) and a student investigator (Y.A.). When
there were differences in coding, the investigators reached consen-
sus in a case conference with a third investigator (either A.F. or
M.B.).
Outcome measures
After 12 months (t = 12), medication records were collected to
analyse the drug changes. The outcomes could only be assessed
for patients with complete medication records available for at
least 6 months. The total number of DRPs and recommenda-
tions were assessed by the main investigator (H.K.). Clinical rel-
evance was assessed by the percentage of DRPs assigned a high
priority, the percentage of recommendations for drug change
and the percentage of implemented recommendations for drug
change.
Statistical analysis
All data were analysed using databases (Microsoft Access 2007;
Microsoft Corporation, Redmond, WA, USA) and statistical soft-
ware (SPSS version 17.0; SPSS Inc., Chicago, IL, USA). Descrip-
tive statistics were used for basic characteristics. Pearson
chi-square tests were used for each categorical variable. An
independent t-test was used for comparison of the mean num-
ber of DRPs per patient. A P-value <0Æ05 was considered statis-
tically significant. Differences between the percentages of
clinical relevant DRPs and recommendations identified during
patient interviews and those identified by medication and clini-
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cal records were assessed by odds ratios (OR) and correspond-
ing 95% confidence intervals.
RESULTS AND DISCUSSION
Patient flow
Patients were recruited for the intervention group in 10 commu-
nity pharmacies. A total of 481 patients were eligible for partici-
pation in the intervention group of the study (Fig. 1). Of 396
patients were sent an invitation to participate. Of patients
invited to participate, 188 patients (47%) gave informed consent;
33 patients gave informed consent, but did not actually partici-
pate in the study. The reasons for not participating were loss of
interest (n = 22), patient died (n = 4), health deterioration
(n = 4) and hospital admission (n = 3). Finally, 155 patients were
included in this analysis (response 39%).
Patient characteristics
The median age of the patients was 76 years and 54% was
women (Table 1). A mean of 4Æ2 diagnoses was registered per
patient. The most common registered diagnoses were hyperten-
sion (52%), diabetes mellitus (37%) and hyperlipidaemia (23%).
The mean number of prescribed drugs per patient was 9Æ0
[range, 5–33]. The most commonly prescribed drug groups were
agents acting on the renin-angiotensin system (ACE-inhibitors
and AII antagonists) (72%), antithrombotic agents (70%) and
lipid modifying agents (68%).
DRPs and recommendations in general
For 155 patients, a total of 1565 potential DRPs were identified,
a mean of 10 DRPs per patient [range, 4–21] (Table 2). The most
frequently observed types of DRPs were ‘Drug Selection’ (28%),
‘Undertreated ‘(26%) and ‘Monitoring required’ (23%). DRP sub-
types were most often classified as ‘No indication apparent’
(21%), ‘Condition undertreated’ (18%) and ‘Laboratory monitor-
ing’ (17%).
Of 1565 recommendations, 905 (58%) comprised a recommen-
dation for drug change (mean, 5Æ8 per patient) (Table 3). The
most common recommendations for drug change were ‘Addi-
tion of a drug’ (18%) and ‘Cessation of a drug’ (13%). Fre-
quently recorded recommendations not involving a drug
change were Laboratory Monitoring (19%) and ‘Adjustment of
patient records’ (13%).
Of 905 recommendations for a drug change, 264 (29%) recom-
mendations were implemented as a drug change (Table 4). The
most implemented drug changes were ‘Cessation of a drug’ (58,
23%) and ‘Addition of a drug’ (53, 21%).
DRPs and recommendations in patient interviews
More than a quarter of DRPs and following recommendations
(415; 27%) were identified during patient interviews (Tables 2
and 3).
The DRP types ‘Compliance’ (19% vs. 1Æ6%, P < 0Æ01),
‘Toxicity’ (16% vs. 2Æ5%, P < 0Æ01), ‘Over or underdose’ (14%
vs. 9Æ7%, P = 0Æ02) and ‘Education’ (1Æ7% vs. 0Æ2%, P < 0Æ01)
Eligible:
481 Patients 
No invitation sent: 85 
Death (14 of 85) 
Moved away (12 of 85) 
GP (7 of 85) 





No informed consent: 208
No interest (26 of 208) 
Too burdensome (14 of 208) 
Unknown (178 of 208) 
Did not participate: 33
Death (4 of 33) 
Hospital admission (3 of 33) 
Worsened health (4 of 33) 
Loss of interest (22 of 33) 
Participating:
155 Patients 
Fig. 1. Patient flow chart.
Table 1. Baseline sociodemographic, medical and drug-related
characteristics of 155 patients
Female (n, %) 84 54%
Age, year (median, interquartile range] 76 72–81
Number of prescription drugs (mean per
patient ±SD)
9Æ0 3Æ6
Medical history, No. (%)
Hypertension 75 52%
Diabetes mellitus 53 37%
Hyperlipidaemia 33 23%
Coronary artery disease 27 19%
Pulmonary disease 23 16%
Arrhythmia 24 17%




Heart failure 12 8%
Most prescribed drug groups (ATC), No. (%)
Agents acting on the renin-angiotensin
system (C09)
112 72%
Antithrombotic agents (B01A) 109 70%
Lipid-modifying agents (C10A) 106 68%
Beta blocking agents (C07A) 80 52%
Drugs for peptic ulcer and GORD (A02B) 68 44%
Calcium channel blockers (C08C) 50 32%
Drugs for obstructive airway diseases (R03) 51 33%
Drugs used in diabetes (A10) 48 31%
Benzodiazepine derivatives (N05BA, N05CD) 35 23%
High-ceiling diuretics (C03C) 33 21%
Low-ceiling diuretics (C03A, C03B, C03E) 31 20%
ª 2012 Blackwell Publishing Ltd Journal of Clinical Pharmacy and Therapeutics, 2012, 37, 674–680
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were relatively more identified during patient interviews,
whereas ‘Monitoring’ (30Æ4% vs. 2Æ2%, P < 0Æ01) and ‘Under-
treated’ (28% vs. 19%, P < 0Æ01) were more frequently identi-
fied from medication and clinical records (Table 2). ‘Toxicity,
allergic reaction or adverse effect present’ (16% vs. 3%,
P < 0Æ01), ‘Taking too little’ (9% vs. 0Æ3%, P < 0Æ01) and
‘Incorrect or unclear dosing instructions’ (9% vs. 2%,
P < 0Æ01) were the main DRP subtypes that were more fre-
quently identified during patient interviews (Table 2). Exam-
ples of specific DRP subtypes in patient interviews are
shown in Box 1.
Table 2. Comparison of number and type of DRPs identified
from medication and clinical records compared to patient inter-
views for 155 patients










P-valueN % N %
D(rug selection) 317 28 118 28 0Æ74
Duplication 9 0Æ8 3 0Æ7 0Æ91
Drug interaction 9 0Æ8 6 1Æ5 0Æ23
Contra-indications
apparent
67 5Æ8 7 1Æ7 <0Æ01
No indication apparent 221 19 102 24 0Æ02
Other drug selection
problem
11 1Æ0 0 0Æ0 0Æ05
O(ver or underdose) 111 10 58 14 0Æ02
Prescribed dosage too
high
24 2Æ1 9 2Æ2 0Æ92
Prescribed dosage too
low
60 5Æ2 12 2Æ9 0Æ05
Incorrect or unclear
dosing instructions
27 2Æ3 37 8Æ9 <0Æ01
C(ompliance) 18 1Æ6 78 19 <0Æ01
Taking too little 4 0Æ3 39 9Æ4 <0Æ01
Taking too much 2 0Æ2 6 1Æ4 0Æ02
Difficulty using dosage
form
12 1Æ0 33 8Æ0 <0Æ01
U(ndertreated) 324 28 78 19 <0Æ01
Condition undertreated 223 20 56 14 0Æ04
Condition untreated 57 5Æ0 20 4Æ8 0Æ94
Preventive therapy
required
34 3Æ0 2 0Æ5 <0Æ01
M(onitoring) 350 30 9 2Æ2 <0Æ01
Laboratory monitoring 260 23 1 0Æ2 <0Æ01
Non-laboratory
monitoring
90 7Æ8 8 1Æ9 <0Æ01
E(ducation) or
information
2 0Æ2 7 1Æ7 <0Æ01
Disease management or
advice
2 0Æ2 7 1Æ7 <0Æ01




29 2Æ5 66 16 <0Æ01
Mean per patient, SD 7Æ4 ± 3Æ0 2Æ7 ± 2Æ0 <0Æ01
DRP, drug-related problem.
Table 3. Comparisons of number and type of recommendations
identified from medication and clinical records compared to














P-valueN % N %
Recommendations for
drug change
603 52 302 73 <0Æ01
Cessation of drug 135 12 70 17 0Æ01
Dose increase 75 6Æ5 23 5Æ5 0Æ48
Dose decrease 38 3Æ3 25 6Æ0 0Æ02
Addition of drug 219 19 56 14 0Æ01
Replacement of drug 103 9Æ0 61 15 <0Æ01
Dose frequency/
schedule change
28 2Æ4 46 11 <0Æ01
Drug formulation
change
5 0Æ4 19 4Æ6 <0Æ01
Recommend dose
administration aid
0 0Æ0 3 0Æ7 <0Æ01
Mean per patient, SD 3Æ9 ± 1Æ9 1Æ9 ± 1Æ6 <0Æ01
Other recommendations 547 48 113 27 <0Æ01
Education/
counselling session
16 1Æ4 33 8Æ0 <0Æ01
Monitoring:
Non-laboratory
86 7Æ5 13 3Æ1 <0Æ01
Monitoring:
Laboratory
280 24 11 2Æ7 <0Æ01
Adjustment of
patient records
156 14 40 9Æ6 0Æ04
Other 9 0Æ8 14 3Æ4 <0Æ01
Mean per patient, SD 3Æ5 ± 1Æ9 0Æ7 ± 0Æ9 <0Æ01
Table 4. Comparison of the clinical relevance of drug-related










[CI 95%] P-valueN % N %
Overall (reference) 1150 415 ref








145 13 120 29 2Æ8 [2Æ1–3Æ7] <0Æ01
DRP, drug-related problem.
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BOX 1. EXAMPLES OF DRPS IDENTIFIED DURING PATIENT INTERVIEWS
Gender,
age (years) Example of DRP DRP subtype
Assigned
priority
#, 75 Despite use of two antihypertensives (nifedipine 30 mg retard once daily,
candesartan 16 mg once daily), measurement at home shows a very high
systolic blood pressure of 198 mmHg
Condition undertreated High
$, 79 Uses nitroglycerine almost daily at 5 pm because of dyspnoe. She experiences
flushes. Also, uses isosorbide mononitrate 60 mg once daily and diltiazem
60 mg three times a day. Next to cardiovascular medication uses a combined
budesonide and salmeterol inhaler two times a day
Condition undertreated High
#, 83 Uses betamethason ointment every day without using an emollient. Complains
about delayed healing of wounds
Condition undertreated High
$, 78 Has restarted alendronic acid without consulting physician. Thought this was a
preventive measure during use of iron tablets. Stopped taking prednisolone a
half year before the interview and does not suffer from osteoporosis according
to the clinical data
No indication apparent High
$, 70 Takes levothyroxin at 9 am Did not know that this has to be taken half an hour
before breakfast
Incorrect or unclear dosing
instructions
High
$, 65 Intermittently uses furosemide 60 mg for facial oedema No indication apparent Medium
$, 75 Uses a coumarin and experiences severe bleeding during blood sampling. Suffers
from itching in the evening, especially when the heater goes on and suspects
this is an adverse effect
Toxicity, allergic reaction or
adverse effect present
Medium
#, 76 Experiences hoarseness during use of beclomethason 100 lg three doses at once
after breakfast
Toxicity, allergic reaction or
adverse effect present
Medium
#, 73 Uses metformine 850 mg once daily instead of the prescribed 3 times a day
because of gastrointestinal problems. Is of the opinion that he gets prescribed
too many medicines. Except metformin uses a long-acting insulin before the
night and a short acting insulin before meals
Taking too little Medium
#, 76 Uses six different medicines (fosinopril pantoprazol, metoprolol, acetylsalicylic
acid, atorvastatin and alfuzosin) at different dosing moments, whereas these
could be taken at the same time
Incorrect or unclear dosing
instructions
Low
$, 75 Uses half a tablet of 80 mg sotalol twice daily, whereas 40 mg tablets are
available and would be more convenient
Incorrect or unclear dosing
instructions
Low




‘Dose frequency/schedule change’ (11% vs. 2Æ4%, P < 0Æ01) and
‘Drug formulation change’ (5% vs. 0Æ4%, P < 0Æ01) were more
often recommended based on patient interviews (Table 3). Both
recommendations were also more often implemented: ‘Dose fre-
quency/schedule change’ (7Æ4% vs. 1Æ5%, P < 0Æ01) and ‘Drug
formulation change’ (1Æ4% vs. 0Æ1%, P = 0Æ03).
Clinical relevance of DRPs
Drug-related problems assigned a high priority were more likely
to be identified during patient interviews than from medication
and clinical records (OR = 1Æ8 [1Æ4–2Æ2]; P < 0Æ01) (Table 4). Exam-
ples of DRP subtypes identified during patient interviews with
high, medium and low priority are shown in Box 1.
Furthermore, DRPs followed by recommendations for a drug
change were more likely to be identified during patient inter-
views (OR = 2Æ4 [1Æ9–3Æ1], P < 0Æ01) (Table 3 and 4).
Finally, DRPs followed by implemented recommendations for
drug change were more likely to be identified during patient
interviews (28% vs. 12%; OR = 2Æ8 [2Æ1–3Æ7]; P < 0Æ01) (Table 4).
This study shows that patient interviews at home contribute sig-
nificantly to the identification of clinical relevant DRPs. Not
only were more than a quarter of all DRPs identified during
patient interviews, the DRPs identified during patient inter-
views were also assigned higher priorities and more frequently
led to recommendations involving a drug change and were
more enacted compared to DRPs identified from clinical and
medication records.
The relative contribution of patient interviews to identification
of all DRPs in our study was comparable to findings of Krska
(29%) in primary care.6 Studies with patient interviews in
other settings reported higher percentages (GP’s office 73%,
hospital 40%), but the intervention and population in
these studies were also quite different.3,7 In addition, in our
study, 53% of the DRPs in patient interviews were assigned a
high priority, and 73% were followed by a recommendation
involving a drug change. The only study that previously
looked into the clinical relevance of DRPs identified
by patient interviews was performed in hospitalized
patients and assessed that 65% of these DRPs were of high
relevance.3
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‘Toxicity, allergic reaction or adverse effect present’ was the most
frequent DRP subtype that was identified in patient interviews.
This was also the most common pharmaceutical care issue in the
study of Krska.6 This finding gives support to the assumption that
the concerns of the patient were sufficiently addressed by the
community pharmacists in the home visits. This is not always
obvious, because analysis of taped consultations from the
HOMER study suggested that pharmacist reviewers were primar-
ily concerned with compliance and knowledge of drugs.16,25
‘Taking too little’ was the second DRP subtype that was signifi-
cantly more identified during patient interviews. Compliance
issues are mentioned as DRPs in many studies with patient
interviews.6,26,27 Sturgess showed that clinical medication
review including patient interviews even improved compliance
measured by self-reporting and refill rate.27 Repeated domicili-
ary visits after initial medication review may also enhance com-
pliance as was measured by pill counts.28 Their explanation was
that compliance issues might be discussed easier in a patient’s
home than in a busy community pharmacy.26
‘Incorrect or unclear dosing instructions’ was the third DRP
subtype that was identified significantly more in patient inter-
views. The corresponding recommendation ‘Dose frequency/
schedule change’ was often implemented. For many patients,
minor changes in their dose schedule can diminish the fre-
quency of dosing. As shown in an example in Box 1, some
patients are taking medication throughout the whole day,
whereas these could be taken at the same time. In an earlier
domiciliary interviewing study, half of the patients judged that
medication management was a major daily preoccupation, and
spouses were often required to assist.28
It could be questioned whether patient interviews at home
reveal additional or other type of DRPs than patient interviews
in a consulting area in the community pharmacy or GP prac-
tice; however, this was not the aim of this study. On the one
hand, patient interviews at home may elicit more and other
DRPs, because patients might feel more comfortable at home
and therefore are more likely to share their experiences and
concerns about their medicines. This is illustrated by the find-
ing that compliance issues and adverse effects were frequently
identified by patient interviews in our study and Krska’s
study.6 Furthermore, all medicines were available at home,
whereas patients invited to the pharmacy or GP practice might
forget to bring part of their medicines, especially those that
are used intermittently.8 Finally, certain medication-risk factors,
for example, lack of medication administration routine, multi-
ple storage locations, hoarding and medication storage condi-
tions seem only to be identified by home visits.26,28–30 On the
other hand, costs of home visits are also higher. Future studies
should focus on cost effectiveness of patient interviews at
home compared to interviews conducted at a GP practice or
pharmacy.
This study had several strengths. Firstly, the intervention in
our study comprised a clinical medication review meaning that
all data were available to conduct a medication review. Next
to the availability of all clinical records of the patients, addi-
tional laboratory values and blood pressure values were
obtained as part of the RCT. Despite the availability of all
these data, more than a quarter of all DRPs were identified
from patient interviews. Secondly, a very detailed and accurate
description of DRPs was possible, because all pharmaceutical
care plans and reports of patient interviews were electronically
sent by the community pharmacists to the pharmacist review-
ers. This made it also possible to distinguish very clearly
between DRPs identified from medication and clinical records
and from patient interviews without any overlapping. Thirdly,
DRPs were assigned a priority by the pharmacist reviewers’
panel, and this could be seen as an indicator of clinical rele-
vance. Fourthly, patient interviews were conducted by commu-
nity pharmacists. More than half of the DRPs identified from
these patient interviews had a high priority. In an earlier
study, in which patient interviews were conducted by phar-
macy or practice assistants, only a quarter of identified DRPs
had potential clinical relevance.31 Finally, the use of experi-
enced pharmacist reviewers probably led to more complete
and standardized pharmaceutical care plans.
There are some limitations associated with this study. Firstly,
a considerable part of the invited patients (53%) did not give
informed consent. However, our target group is an older
population who have a considerable disease burden. In
particular, the extra laboratory monitoring that was part of
the study was not appreciated by many potential partici-
pants. Secondly, community pharmacists had a short course
(2-days) in medication review and had limited experience in
conducting medication reviews. Finally, each initial pharma-
ceutical care plan by a community pharmacist was adjusted
and completed by well-trained pharmacist reviewers who
had no relationship with patients. Although standardization
is a strength of the study, it may limit generalizability to
daily clinical practice where pharmacists might identify less
DRPs, but have a relationship with patients. Future research
should further elaborate on the role of both the community
pharmacists and the pharmacist reviewers regarding the
identification of DRPs.
WHAT IS NEW AND CONCLUSION
Patient interviews by community pharmacists have a major con-
tribution in the identification of DRPs. This implies that, in gen-
eral, medication review without a patient interview may lead to
fewer clinical relevant recommendations.
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